TaiMed Completes Phase 2b Enrollment for TMB-365/380 HIV Therapy
TaiMed completes Phase 2b enrollment for TMB-365/380, an HIV therapy candidate designed to eliminate pre-treatment susceptibility screening requirements.
Infex’s RESP-X Shows Exacerbation Reduction in Bronchiectasis Study
Infex's RESP-X showed reduced exacerbation rates in non-cystic fibrosis bronchiectasis patients colonized with Pseudomonas aeruginosa in Phase IIa data.
Tedopi Plus Pembrolizumab Met Primary Endpoint in TEDOVA Ovarian Cancer Trial
Tedopi Plus Pembrolizumab met its primary endpoint in the TEDOVA trial, reducing progression or death risk by 47% in...
BIIB122 Fails to Slow Parkinson’s Progression Despite Strong Target Engagement
BIIB122 failed to slow Parkinson's progression in a Phase 3 trial despite achieving over 90% target engagement in 648...
When Phase 2b Wins and Phase 3 Fails: The Biomarker Stratification Crisis Hidden Inside Astegolimab’s COPD Data
Genentech's astegolimab cut COPD exacerbations in ALIENTO but missed significance in Phase 3 ARNASA—exposing a broken biomarker stratification logic...
Infex RESP-X shows safety, reduces exacerbations in bronchiectasis trial
Infex RESP-X shows safety, reduces exacerbations in bronchiectasis trial. Quarterly dosing monoclonal targets pseudomonas virulence.
TaiMed Biologics Completes Phase 2b Enrollment for TMB-365/380 HIV Therapy
TaiMed Biologics completes Phase 2b enrollment for TMB-365/380 HIV therapy, a dual antibody combination dosed every two months without...
Nuvalent to Present Neladalkib and Zidesamtinib Data at 2026 ASCO
Nuvalent neladalkib achieves oral presentation at 2026 ASCO for ALK-positive NSCLC, with NDA filed in April ahead of FDA...
Sapience’s lucicebtide shows 28.4-month median survival in glioblastoma Phase 2
Sapience's lucicebtide demonstrated 28.4-month median progression-free survival in newly diagnosed glioblastoma, significantly exceeding historical benchmarks i
Astegolimab’s Split Verdict: What ALIENTO’s Win and ARNASA’s Miss Reveal About COPD Trial Design
Astegolimab cut COPD exacerbations in Phase 2b but missed in Phase 3—a 14.5% gap that exposes critical flaws in...